Click now and find out how you can influence PBAC.

Click now and find out how you can influence PBAC.

Considering preparing a submission for the National Inquiry into Hepatitis C?

To support the community in having your say Hepatitis Australia has prepared some fact sheets to help you out. Information about how to format your submission, your privacy and some important facts are provided. You can read it online or download a PDF copy to print out.  You can find this information on our Hep C Inquiry page.

Where to lodge your Inquiry submission.

If you are wishing to lodge your own submission to the Parliamentary Inquiry into Hepatitis C in Australia you can do so by visiting There is a link to lodge your submission on the right hand side of the page. 


Hepatitis A - Quick Facts

  • Hepatitis A is an acute (short-term) infection of the liver that can be serious and require medical attention.
  • Hepatitis A is diagnosed by a simple blood test.
  • Hepatitis A is not common in Australia (170 people diagnoses in 2013)
  • Hepatitis A is preventable with good personal hygiene.
  • There is a vaccine for hepatitis A, usually recommended for people travelling to high prevalence countries.
  • For more information visit our Hepatitis A page.

Hepatitis Australia would like to thank the many people who have lodged submissions to the PBAC regarding access to new hepatitis C drugs.

Hepatitis Australia understands there have been many submissions from the community and organisations. Your contributions are valuable and we hope lead to a good outcome from the PBAC meeting in March. We will keep you posted of any further developments.

Federal Health Committee announces inquiry into hepatitis C: Health Committee inquiry marks 2015 as year to turn tide on hepatitis C epidemic

A House of Representatives Health Committee inquiry into hepatitis C should be a catalyst that turns the tide on the rising death toll from hepatitis C-related liver disease.  Hepatitis Australia today welcomed the announcement of an inquiry into hepatitis C, a blood-borne virus that affects more than 230,000 Australians and will claim more than 650 lives this year alone.

 “Many Parliamentarians are acutely aware of the looming tidal-wave of serious liver disease and preventable deaths caused by a lack of regular liver health checks and appallingly low hepatitis C treatment rates.  Today’s announcement shows real leadership by the House of Representatives Health Committee to tackle the problem head-on,” said CEO of Hepatitis Australia, Helen Tyrrell. Read more ...

Update: The Auckland Statement on viral hepatitis - Australian Progress Report 2014

The Auckland Statement was launched at the 8th Australasian Viral Hepatitis Conference in Auckland, New Zealand, in September 2012, and was endorsed by all the leading Australian and New Zealand hepatitis organisations as a blueprint for urgent action on on viral hepatitis. Targets were set for achievement by 2016, and this progress report is provided at the half-way point. This report revisits the targets set in the Auckland Statement and reviews them from the perspective of the Australian response. Download now. (PDF 394.15kb)

click to enlarge

Latest Data on Viral Hepatitis Released.

On 18 September The Kirby Institute released the HIV, viral hepatitis and sexually transmitted infections in Australia: Annual Surveillance Report 2014. The report presents a variety of data which is intended to inform Australia's response to blood borne viruses and STIs.  In a presentation at the 9th Australasian Viral Hepatitis Conference, Hepatitis Australia delivered a presentation which compared the Australian responses to viral hepatitis and HIV.  When looking at the data, it is clear Australia needs to elevate it's response to viral hepatitis to emulate the highly effective response to HIV.  A copy of the presentation report will be available on this site shortly. You can download a copy of the Annual Surveillance Report here


Media statement released, 22 August 2014:

PBAC decisions – a mixed bag for Australians living with Hepatitis C

simeprevir (Olysio)
Hepatitis Australia today welcomed the recommendation to add simeprevir (Olysio) to the Pharmaceutical Benefits Scheme (PBS) for the treatment of genotype 1 chronic hepatitis C.

sofosbuvir (Sovaldi)
Responding to the PBAC decision to reject an application to subsidise the antiviral medication sofosbuvir (Sovaldi), Ms Tyrrell said “it’s a sad day when access to game-changing therapy is denied. This is a bad outcome for people living with hepatitis C”. Read more - Download now. (PDF 245.43kb)


Support Us

You can also donate directly to Hepatitis Australia. Please contribute to our aim of a world without viral hepatitis by making a tax deductible donation. Find out more

Hepatitis Australia is a non-government, not-for-profit organisation that became incorporated in 1997. We do not provide services to individuals. To locate hepatitis services in your area visit the services page or call the Info line on 1300 437 222. Our members consist of the state and territory hepatitis organisations and other key services providing hepatitis services.


Page Updated:  15 July 2014

Latest News